Constraints on the dominant mechanism for HIV viral dynamics in patients on raltegravir

Antiviral Therapy

Volumn 14, Issue 2, 2009, Pages 263-271

  Sedaghat, Ahmad R ^a   Siliciano, Robert F ^a,b   Wilke, Claus O ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; RALTEGRAVIR; 2 PYRROLIDONE DERIVATIVE; INTEGRASE INHIBITOR;

ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS; MACROPHAGE; MATHEMATICAL MODEL; MONOCYTE; PREDICTION; PRIORITY JOURNAL; VIREMIA; VIRUS CELL INTERACTION; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; BIOLOGICAL MODEL; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; VIROLOGY; VIRUS DNA CELL DNA INTERACTION;

CD4-POSITIVE T-LYMPHOCYTES; HIV; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; MODELS, BIOLOGICAL; PYRROLIDINONES; VIREMIA; VIRUS INTEGRATION; VIRUS REPLICATION;

EID: 67149113903     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Bonhoeffer S, May RM, Shaw GM, Nowak MA. Virus dynamics and drug therapy. Proc Natl Acad Sci U S A 1997; 94:6971-6976.
2. Polis MA, Sidorov IA, Yoder C, et al. Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy. Lancet 2001; 358:1760-1765.
3. Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007; 46:125-133.
4. Murray JM, Emery S, Kelleher AD, et al. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 2007; 21:2315-2321.
5. Zolopa AR, Mullen M, Berger D, et al. The HIV integrase inhibitor GS-9137 demonstrates potent antiretroviral activity in treatment-experienced patients. 14th Conference on Retroviruses and Opportunistic Infections. 25-28 February 2007, Los Angeles, CA, USA. Abstract 143LB.
6. Sedaghat AR, Dinoso JB, Shen L, Wilke CO, Siliciano RF. Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc Natl Acad Sci U S A 2008; 105:4832-4837.
7. Markowitz M, Louie M, Hurley A, et al. A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J Virol 2003; 77:5037-5038.
8. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387:188-191.
9. Pierson TC, Zhou Y, Kieffer TL, et al. Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection. J Virol 2002; 76:8518-8531.
10. + T cell reservoir for HIV-1 in the setting of HAART. BMC Infect Dis 2008; 8:2.
11. Koelsch KK, Liu L, Haubrich R, et al. Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. J Infect Dis 2008; 197:411-419.
12. + T cells. J Virol 2005; 79:2199-2210.
13. Rouzine IM, Sergeev RA, Glushtsov AI. Two types of cytotoxic lymphocyte regulation explain kinetics of immune response to human immunodeficiency virus. Proc Natl Acad Sci U S A 2006; 103:666-671.
14. Muller V, Vigueras-Gomez JF, Bonhoeffer S. Decelerating decay of latently infected cells during prolonged therapy for human immunodeficiency virus type 1 infection. J Virol 2002; 76:8963-8965.
15. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271:1582-1586.
16. + T cell reservoir for HIV in patients on HAART. PLoS Pathog 2007; 3:e122.
17. Matthews GV, Sabin CA, Mandalia S, et al. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS 2002; 16:53-61.
18. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358:2095-2106.
19. Shen L, Peterson S, Sedaghat AR, et al. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med 2008; 14:762-766.
20. Dixit NM, Markowitz M, Ho DD, Perelson AS. Estimates of intracellular delay and average drug efficacy from viral load data of HIV-infected individuals under antiretroviral therapy. Antivir Ther 2004; 9:237-246.
21. Louie M, Hogan C, Di MM, et al. Determining the relative efficacy of highly active antiretroviral therapy. J Infect Dis 2003; 187:896-900.
22. Notermans DW, Goudsmit J, Danner SA, et al. Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen. AIDS 1998; 12:1483-1490.
23. Arribas JR. Efavirenz: enhancing the gold standard. Int J STD AIDS 2003; 14 Suppl 1:6-14.
24. Hammer SM, Eron JJ, Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570.
25. Evering TH, Markowitz M. Raltegravir: an integrase inhibitor for HIV-1. Expert Opin Investig Drugs 2008; 17:413-422.
26. Wong JK, Lampiris H. Covering all the bases: targeting HIV-1 integrase. J Acquir Immune Defic Syndr 2006; 43:507-508.
27. Aquaro S, Calio R, Balestra E, et al. Clinical implications of HIV dynamics and drug resistance in macrophages. J Biol Regul Homeost Agents 1998; 12:23-27.
28. Arfi V, Riviere L, Jarrosson-Wuilleme L, et al. Characterization of the early steps of infection of primary blood monocytes by human immunodeficiency virus type 1. J Virol 2008; 82:6557-6565.
29. Neil S, Martin F, Ikeda Y, Collins M. Postentry restriction to human immunodeficiency virus-based vector transduction in human monocytes. J Virol 2001; 75:5448-5456.
30. Al-Mawsawi LQ, Al-Safi RI, Neamati N. Anti-infectives: clinical progress of HIV-1 integrase inhibitors. Expert Opin Emerg Drugs 2008; 13:213-225.